# Nuclide record artbio (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/artbio/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "artbio" ;
  schema:name "ARTBIO"@en ;
  schema:description "ARTBIO makes cancer treatments that deliver short-range alpha radiation from lead-212 directly to tumour cells, starting with prostate cancer. Its first medicine is in early human trials, currently paused by the company while it reviews data."@en ;
  schema:url <https://nuclide.cc/companies/artbio/>, <https://artbio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://artbio.com/>, <https://www.prnewswire.com/news-releases/artbio-announces-dosing-of-two-cohorts-with-ab001-in-artisan-a-phase-1-alpha-radioligand-therapy-clinical-trial-for-metastatic-castration-resistant-prostate-cancer-302657972.html>, <https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/>, <https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> .